Evidence map›Paper›PMID 42294085›Full record

ArticleIEEE control systems letters2026

Trajectory Landscapes for Therapeutic Strategy Design in Agent-Based Tumor Microenvironment Models.

Eric Cramer, Laura M Heiser, Young Hwan Chang

Abstract read
In one paragraph

Article in IEEE control systems letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eric CramerDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97239, USA.
Laura M HeiserDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97239, USA.
Young Hwan ChangDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97239, USA.

Funding

Medical Scientist Training Program of Oregon Health & Science UniversityT32GM141938 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI CHEN, YABING · 2021 to 2025
$4.6M
Integrated Training in Quantitative and Experimental Cancer Systems BiologyT32CA254888 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Sudarshan Anand, LISA M COUSSENS · 2021 to 2026
$2.2M
High Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0M
NCI NIH HHS T32 CA254888NIGMS NIH HHS T32 GM141938NIH HHS S10 OD034224
6 · The paper itself

Abstract

Multiplex tissue imaging (MTI) enables high-dimensional, spatially resolved measurements of the tumor microenvironment (TME), but most clinical datasets are temporally undersampled and longitudinally limited, restricting direct inference of underlying spatiotemporal dynamics and effective intervention timing. Agent-based models (ABMs) provide mechanistic, stochastic simulators of TME evolution; yet their high-dimensional state space and uncertain parameterization make direct control design challenging. This work presents a reduced-order, simulation-driven framework for therapeutic strategy design using ABM-derived trajectory ensembles. Starting from a nominal ABM, we systematically perturb biologically plausible parameters to generate a set of simulated trajectories and construct a low-dimensional trajectory landscape describing TME evolution. From time series of spatial summary statistics extracted from the simulations, we identify a switched Markov State Model (MSM) that captures metastable states and the transitions between them, and whose modes are indexed by the parameter regimes most predictive of terminal-state outcome within the sampled ensemble. To connect simulation dynamics with clinical observations, we map patient MTI snapshots onto the landscape and assess concordance with observed spatial phenotypes and clinical outcomes. We further show that conditioning the MSM on the most predictive parameters yields group-specific transition models to formulate a finite-horizon Markov Decision Process (MDP) and use it for reachability analysis and finite-horizon intervention design. The resulting framework enables simulation-grounded therapeutic policy design for partially observed biological systems without requiring longitudinal patient measurements, taking a step towards adaptive, state-aware therapeutic strategies in oncology.

Indexed as

Agent-based modelsimmunotherapyMarkov state modelstime-delay embeddingtumor microenvironment

Identifiers

PMID42294085
PMCPMC13262968

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.